The LinkedIn activities of AstraZeneca employees have yet again landed the drugmaker in hot water, with the U.K. marketing ...

If the Phase III trials of the oral GLP-1RA are successful, AstraZeneca is set to join a fast-growing market.

AstraZeneca (LSE:AZN) is advancing its oral GLP-1 candidate elecoglipron into Phase 3 trials after positive Phase 2b results.

AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout ...

A new GLP-1 oral medication from AstraZeneca, known as elecoglipron, lowered blood sugar levels and led to 10.5% weight loss ...

AstraZeneca (AZN) stock is in focus as the FDA approves a label expansion for its breast cancer therapy Truqap in prostate ...

Alison Dziarmaga, Vice President and U.S. Breast Cancer Franchise Head at AstraZeneca, ...

The approval relies on positive data from the POTOMAC Phase III trial.

AstraZeneca's drug Truqap in combination with two other medications secured approval for the treatment of a form of advanced prostate cancer by the Food and Drug Administration. Approval was based on ...

PARIS — A new pill developed by the British pharma firm AstraZeneca appears to help people lose a similar amount of weight to ...

AstraZeneca is emerging as a potential new contender in the booming obesity treatment market after its experimental ...

AstraZeneca said on Monday that patients lost 10.5% of their body weight after 26 weeks in a mid-stage trial of ​its ...